"Sales from a PCAP combination could easily approach a billion dollars within 2-3 years"
Let's keep our eye on the real opportunity, shall we.
Per Dr. Wurlitzer - forget blogs, forget Feurstein - neither of which know squat about the science behind biotech
That quote is from an interview conducted 11/14/11, the real reason longs are in this stock.
"Sales from a PCAP combination could easily approach a billion dollars within 2-3 years throughout the world provided there are satisfactory major pharmaceutical companies doing the marketing. The emergence of AEZS 108 in 2-4 years for treating refractory ovarian and endometrial cancer would definitely have blockbuster potential.
So many variables are present that attempting a future value analysis discounted back to present value is risky. Yet, AEZS unmistakeably has the potential to be a multi-billion dollar company within 10 years if it is not bought out before then."